WHAT: A Celebration of Technology and Innovation
Panel Discussion: Translating Ideas Into Products Awards and reception followed by cocktails and hors d'oeuvres
WHEN: Tuesday, May 8, 2007, 4:00-7:00 p.m.
WHERE: Emory Conference Center, 1615 Clifton Rd., Atlanta
WHO: Emory entrepreneurs and Atlanta biotech leaders
R. Wayne Alexander, MD, PhD, R. Bruce Logue Chair of Medicine, Emory University; Co-founder, AtheroGenics
Ernest V. Garcia, PhD, Professor of Radiology, Emory University; Founder, Syntermed, Inc.
Dennis C. Liotta, PhD, Samuel Candler Dobbs Professor of Chemistry, Emory University; Co-Inventor, Emtriva, Epivir, Combivir, Truvada, Atripla, etc.; Co-Founder, Metastatix Inc., Curry Pharmaceuticals, Slainte Biologicals, iThemba
Raymond F. Schinazi, PhD, DSc, Professor of Pediatrics and Director, Laboratory of Biochemical Pharmacology, Emory University; Co-Inventor, Emtriva, Epivir, Combivir, Truvada, Atripla, etc.; Founder, Pharmasset, Inc.; Idenix Pharmaceuticals, Ltd., Co-Founder, Triangle Pharmaceuticals (now part of Gilead Sciences)
Todd Sherer, PhD, Associate Vice President of Research Administration and Director of Technology Transfer, Emory University
Thomas H. Callaway, MD, MBA, Managing Partner, Georgia Venture Partners
A presentation by Emory's boldest and most successful biotech entrepreneurs will chronicle the rise of Emory's technology transfer program along with the personal research experiences that continue to result in commercialized products.
Emory University ranked first nationally in commercialization revenue among universities in the most recent ranking of the Association of University Technology Managers (AUTM). Although the $585 million in licensing revenue included a one-time payment of $540 million from the sale of future royalties from the Emory-discovered HIV/AIDS drug Emtriva, over the past 15 years commercialized Emory research discoveries have resulted in revenues in excess of $720 million to the University,
Emory's technology transfer program has one of the most robust product pipelines of any university in the country, with one of the nation's leading programs for guiding technology developed in the laboratory through the patenting and licensing process to the marketplace and into the hands of consumers. The program has resulted in 16 licensed therapeutic products already in the marketplace and 38 licensed products in various stages of drug discovery, clinical development or regulatory approval. In addition, 37 companies have been started around Emory's technology, leading to nine publicly traded companies and seven companies selling product on the market.